Twist Bioscience (NASDAQ:TWST) Price Target Increased to $48.00 by Analysts at Scotiabank

Twist Bioscience (NASDAQ:TWST) had its price target lifted by Scotiabank from $43.00 to $48.00 in a report released on Monday, Benzinga reports. The brokerage presently has a “sector outperform” rating on the stock. Scotiabank’s price objective would indicate a potential upside of 7.43% from the company’s current price.

Several other equities analysts also recently weighed in on TWST. Barclays raised their price target on Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a report on Friday. The Goldman Sachs Group upgraded shares of Twist Bioscience from a “neutral” rating to a “buy” rating and raised their price objective for the company from $25.00 to $45.00 in a research note on Wednesday, January 17th. Evercore ISI upped their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday. Finally, Robert W. Baird increased their price target on shares of Twist Bioscience from $39.00 to $40.00 and gave the company an “outperform” rating in a report on Friday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Twist Bioscience currently has an average rating of “Buy” and a consensus price target of $42.50.

Twist Bioscience Stock Up 8.4 %

Shares of NASDAQ:TWST traded up $3.47 during trading on Monday, hitting $44.68. The stock had a trading volume of 1,390,490 shares, compared to its average volume of 979,696. The company has a market capitalization of $2.60 billion, a PE ratio of -13.26 and a beta of 1.64. The firm’s fifty day moving average is $34.03 and its 200 day moving average is $31.14. Twist Bioscience has a 12 month low of $11.81 and a 12 month high of $44.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The business had revenue of $75.30 million during the quarter, compared to the consensus estimate of $70.70 million. During the same quarter in the prior year, the company earned ($1.06) earnings per share. The firm’s quarterly revenue was up 25.1% compared to the same quarter last year. Equities research analysts expect that Twist Bioscience will post -3.17 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,487 shares of Twist Bioscience stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $37.43, for a total value of $55,658.41. Following the sale, the chief executive officer now directly owns 516,409 shares of the company’s stock, valued at $19,329,188.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Twist Bioscience news, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total transaction of $37,810.56. Following the completion of the transaction, the chief executive officer now owns 515,281 shares in the company, valued at $17,272,219.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 1,487 shares of the stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total transaction of $55,658.41. Following the completion of the transaction, the chief executive officer now directly owns 516,409 shares of the company’s stock, valued at approximately $19,329,188.87. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,211 shares of company stock valued at $449,573. Corporate insiders own 3.92% of the company’s stock.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently made changes to their positions in the company. Artisan Partners Limited Partnership increased its stake in Twist Bioscience by 111.3% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after purchasing an additional 1,961,621 shares during the period. Invesco Ltd. boosted its position in Twist Bioscience by 1,496.2% during the 3rd quarter. Invesco Ltd. now owns 831,006 shares of the company’s stock valued at $16,836,000 after acquiring an additional 778,944 shares in the last quarter. ARK Investment Management LLC increased its holdings in shares of Twist Bioscience by 6.3% in the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after acquiring an additional 427,274 shares during the period. AEGON ASSET MANAGEMENT UK Plc bought a new position in shares of Twist Bioscience in the 4th quarter worth $11,956,000. Finally, Norges Bank purchased a new stake in shares of Twist Bioscience during the 4th quarter worth $10,766,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.